Psyched Wellness Ltd (CSE:PSYC, OTCQB:PSYCF) said it has received positive feedback from test subjects who participated in the pilot run of 300 bottles of Calm, the first legal Amanita Muscaria extract available for sale in the US.
The feedback provided the necessary information to determine the final flavour formulation for Calm, the company said, adding that pre-orders are now sold out and shipping will commence mid to end-October.
"We have taken a cautious approach to bringing our flagship product, Calm, to market. We have been working closely with Vantage Hemp, our contract manufacturer and providing them with the feedback from our test participants to ensure we produce the best version of Calm for our consumers," Jeffrey Stevens, CEO of the company said in a statement.
READ: Psyched Wellness inks key supply agreements ahead of anticipated launch of its first Amanita Muscaria mushroom-derived product Calm
The pilot run found that an ideal dose will range from 1ml to 2ml depending on the user's familiarity with Amanita Muscaria products and that the majority of the test subjects experienced the desired effects of a calming and relaxing sensation. Additionally, the majority of test subjects felt that they woke the next day well-rested and with little to no grogginess. The pilot run also helped identify extraction efficiencies that will enhance production, increasing efficiency and lowering cost of goods.
"These are very exciting times!'' said David Shisel, COO of the company.
"Shipping CALM, our Amanita Muscaria product that we are all using for our wellness, to real customers outside of our internal focus groups, marks a very significant milestone in our company's progression. We are extremely excited for everyone to try it."
Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
Contact the author at jon.hopkins@proactiveinvestors.com